The future of immuno-oncology drug development is positioned in combination therapies, where immunotherapy modalities are tested in rational combinations with other immunotherapies or targeted therapies for synergistic effects. Combination immunotherapy promises to...
The Immuno-Oncology Biomarkers Workshop will identify the next steps for action in immunotherapy biomarker development. It will provide a forum for energetic discussion about the collaborative efforts across several societies and consortia, make progress on...
